Drug carrier as well as preparation method and application thereof

Through the nanocarrier technology of amphiphilic prodrug compounds, the problem of blood-brain barrier penetration is solved, efficient drug delivery and tumor suppression is achieved, new methods for diagnosis and treatment of brain gliomas are provided, and the organization of traditional methods is avoided. damage.

CN119055781APending Publication Date: 2024-12-03DALIAN NATIONALITIES UNIVERSITY
View PDF 0 Cites 2 Cited by

Patent Information

Application Number
CN202411246966.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-06
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

The prior art is difficult to effectively cross the blood-brain barrier to deliver drugs to brain glioma lesions, and traditional methods such as sonication may lead to tissue damage and chronic inflammation.

Method used

Nanocarriers were prepared by thin-film ultrasonic dispersion method using amphiphilic prodrug compounds to increase drug solubility and penetration, and load contrast agents and photosensitizers to achieve self-assembly and combined treatment of drugs.

Benefits of technology

It has achieved efficient penetration of the blood-brain barrier by drugs, maximized tumor growth, and provided new ideas for diagnosis and treatment of brain gliomas, reducing the damage to the blood-brain barrier by treatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119055781A_ABST
    Figure CN119055781A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of biochemistry, and particularly relates to a drug carrier and a preparation method and application thereof, and the preparation method comprises the following steps: fully dissolving an amphiphilic prodrug compound in methanol to obtain a prodrug solution; carrying out nitrogen film blowing on the prodrug solution by using a nitrogen blowing instrument to form a layer of uniform film on the wall of the container, and carrying out vacuum drying overnight for later use; and removing the residual organic solvent from the film, adding ultrapure water, and carrying out water bath and ultrasonic treatment to obtain the drug carrier. The amphiphilic nano-carrier is constructed through a film ultrasonic dispersion method, the solubility of the drug is increased, the in-vivo pharmacokinetic characteristics are improved, a contrast agent, a photosensitizer and the like can be loaded, combined therapy such as chemotherapy / photodynamic therapy and the like can be achieved while diagnosis of brain glioma is achieved, tumor growth is inhibited to the maximum extent, and the application prospect is wide. The design and preparation of the nano-carrier can provide a new thought and a new method for clinical diagnosis and treatment of brain glioma.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of biochemical technology, and specifically relates to a drug carrier and a preparation method and application thereof. Background Art

[0002] Gliomas are one of the most common types of primary brain tumors and can cause significant morbidity and mortality. Since most gliomas are characterized by invasive growth and malignant transformation, they have unclear boundaries with surrounding brain tissues, are prone to recurrence, and are very difficult to treat. The annual incidence of gliomas in my country is 5 / 100,000-8 / 100,000, and the 5-year mortality rate is second only to pancreatic cancer and lung cancer among systemic tumors. There are three main methods for treating gliomas: surgical resection, radiotherapy, and chemotherapy. Due to the characteristics of gliomas, chemotherapy is an indispensable treatment method. However, due to the existence of the blood-brain barrier, it is difficult for drugs to be effectively delivered to the lesion site to exert their therapeutic effects. In addition, studies have shown that damage to the blood-brain barrier is associated with many brain diseases, so how to further develop new drugs and new drug delivery systems on the basis of protecting the blood-brain barrier from damage remains a research focus.

[0003] Based on non-invasive means, nanoparticles represent a new method to cross the blood-brain barrier, such as liposomes, polymer nanoparticles, inorganic nanoparticles, dendritic polymers, etc. Nanoparticles have the characteristics of small size, low toxicity, and controlled drug release. These nanodrugs rely on a variety of nutrient transporters and receptors expressed by brain endothelial cells to cross the blood-brain barrier through transcytosis. However, nanodrugs may interact with red blood cells in the blood circulation and compete with plasma nutrients, resulting in premature or insufficient drug release. Certain immune cells in the tumor microenvironment, such as tumor-associated macrophages, myeloid-derived suppressor cells, and regulatory T cells, induce an immunosuppressive state, thereby limiting the efficacy of chemotherapy.

[0004] The use of external force to open the blood-brain barrier and deliver drugs to the brain currently mainly uses magnetic fields, ultrasound and other means. For example, focused ultrasound combined with microbubbles can open the blood-brain barrier non-invasively and reduce tissue damage, and has been used in clinical trials. Studies have shown that even low-intensity ultrasound treatment can cause harmful chronic inflammation (including vascular damage, edema, etc.). Therefore, it is urgent to provide a new drug carrier for drug delivery to overcome the problems existing in the existing technology. Summary of the invention

[0005] The purpose of the present invention is to provide a drug carrier and a preparation method and application thereof, wherein the drug carrier increases the drug solubility and improves the in vivo pharmacokinetic properties, can penetrate the blood-brain barrier, and inhibit tumor growth to the maximum extent.

[0006] The objective of the present invention is achieved through the following technical solutions: The present invention provides a method for preparing a drug carrier, comprising the following steps: (1) fully dissolving the prodrug compound in an organic solvent to obtain a prodrug solution; (2) blowing nitrogen gas onto the prodrug solution using a nitrogen blowing apparatus to form a uniform film on the container wall, and vacuum drying overnight for later use; (3) Residual organic solvent is removed from the film treated in step (2), ultrapure water is added, and the film is placed in a water bath and subjected to ultrasound to obtain a drug carrier.

[0007] Furthermore, in step (1), the prodrug compound is an amphiphilic prodrug compound comprising a tail of neuraminic acid and a head of a hydrophilic chemotherapeutic drug, and the organic solvent comprises methanol.

[0008] Furthermore, in step (2), the nitrogen blowing film is to place the prodrug solution dissolved in the sample bottle on a nitrogen blowing instrument, and adjust the nitrogen flow rate to make the wall-adherent film uniform and the organic reagent methanol volatilize.

[0009] Furthermore, in step (3), the water bath treatment is carried out at 40-55° C. for 2 hours, and the ultrasonic treatment parameter is 50-100W.

[0010] Furthermore, the preparation method also includes the step of loading substances including contrast agents and photosensitizers.

[0011] The present invention also provides a drug carrier prepared by the preparation method, wherein the drug carrier can penetrate the blood-brain barrier.

[0012] The present invention also provides an application of the drug carrier in preparing anti-tumor drugs.

[0013] Furthermore, the tumor is a glioma.

[0014] The main components of the blood-brain barrier are endothelial cells, pericytes and astrocytes, with endothelial cells playing the main role.

[0015] The endothelial cell membrane is a bilayer membrane structure based on lipids. It is lipophilic and fat-soluble substances can easily pass through it. The degree of fat solubility of a substance also determines the difficulty and speed of its crossing the blood-brain barrier. Neuroacid (NA) and NA-Gem prodrug compounds that can cross the blood-brain barrier have high lipophilicity. As small molecule drugs, NA-Gem prodrug compounds are close to the parameter range of Lipinski's five principles in terms of topological polar surface area, molecular weight and acidity coefficient. The NA-Gem prodrug prepared by the present invention, as an amphiphilic drug, can self-assemble into micelles with a small particle size, which provides the possibility for its passive transport across the blood-brain barrier.

[0016] The beneficial effects of the present invention are: The present invention innovatively synthesizes an amphiphilic prodrug compound, and constructs a nanocarrier through a thin film ultrasonic dispersion method, thereby increasing drug solubility and improving in vivo pharmacokinetic properties. In addition, the nanocarrier can also load contrast agents, photosensitizers, etc., to achieve the diagnosis of brain gliomas, and can also achieve combined treatments such as chemotherapy / photodynamic therapy to maximize tumor growth inhibition. The design and preparation of the novel nanocarrier of the present invention will provide new ideas and methods for the clinical diagnosis and treatment of brain gliomas. BRIEF DESCRIPTION OF THE DRAWINGS

[0017] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0018] Figure 1 This is a diagram of a nervonic acid-gemcitabine prodrug micelle solution containing a nervonic acid-gemcitabine prodrug compound and pyrene in Example 1 of the present invention; Figure 2 The Boltzmann curve of the sample solution containing nervonic acid-gemcitabine prodrug micelles and pyrene in Example 1 of the present invention; Figure 3 TEM morphology of the nanomicelles prepared in Example 1 of the present invention, wherein the scale of the left figure is 100 nm and the scale of the right figure is 50 nm; Figure 4 This is a schematic diagram of a model of nanomicelles penetrating the blood-brain barrier prepared in Example 1 of the present invention; Figure 5 This is a graph showing the effect of NA-Gem on U87-MG cell cytotoxicity in Example 1 of the present invention; Figure 6 This is a graph showing the cytotoxic effect of NA-Gem on hCMEC / D3 cells in Example 1 of the present invention. DETAILED DESCRIPTION

[0019] Various exemplary embodiments of the present invention will now be described in detail. This detailed description should not be considered as limiting the present invention, but should be understood as a more detailed description of certain aspects, features, and embodiments of the present invention.

[0020] It should be understood that the terms described in the present invention are only for describing special embodiments and are not intended to limit the present invention. In addition, for the numerical range in the present invention, it should be understood that each intermediate value between the upper and lower limits of the scope is also specifically disclosed. Each smaller range between the intermediate value in any stated value or stated range and any other stated value or intermediate value in the described range is also included in the present invention. The upper and lower limits of these smaller ranges can be independently included or excluded in the scope.

[0021] Unless otherwise indicated, all technical and scientific terms used herein have the same meanings as those generally understood by those skilled in the art. Although the present invention describes only preferred methods and materials, any methods and materials similar or equivalent to those described herein may also be used in the implementation or testing of the present invention. All documents mentioned in this specification are incorporated by reference to disclose and describe the methods and / or materials associated with the documents. In the event of a conflict with any incorporated document, the content of this specification shall prevail.

[0022] It will be apparent to those skilled in the art that various modifications and variations may be made to the specific embodiments of the present invention description without departing from the scope or spirit of the present invention. Other embodiments derived from the present invention description will be apparent to those skilled in the art. The present invention description and examples are exemplary only.

[0023] The words “include,” “including,” “have,” “contain,” etc. used in this document are open-ended terms, meaning including but not limited to.

[0024] The brain glioma prodrug of the present invention consists of two parts: the tail of neuraminic acid and the head of the hydrophilic chemotherapy drug.

[0025] Neuroacid (NA) is the main fatty acid found in various sphingolipid species in the central nervous system. It can easily cross the blood-brain barrier and reach the brain tissue, and has important biological functions in medical care for brain development and injury repair. In addition, neuraminic acid also has a modifiable carboxyl group, so it can form an acid-sensitive linker with water-soluble chemotherapeutic drugs to prepare amphiphilic prodrug compounds that can penetrate the blood-brain barrier.

[0026] Among them, HATU used in the following text was purchased from Shanghai Aladdin Biochemical Technology Co., Ltd.; DIPEA was purchased from Tianjin Comeo Chemical Reagent Co., Ltd.; DMF was purchased from Tianjin Comeo Chemical Reagent Co., Ltd.; gemcitabine was purchased from Shanghai Aladdin Biochemical Technology Co., Ltd.; neuraminic acid was purchased from Shanghai Ronghe Pharmaceutical Technology Development Co., Ltd.; DMEM was purchased from Thermo Fisher Scientific; fetal bovine serum was purchased from Ekosai Technology Co., Ltd.; bispecific antibodies were purchased from Beyotime Biotechnology Co., Ltd.; and CCK-8 was purchased from Shanghai Weihuan Biotechnology Co., Ltd.

[0027] Specific preparation method of brain glioma prodrug: Take nervonic acid (1 mmol) and dissolve it in a DMF solution containing HATU and DIPEA (the ratio of nervonic acid to activator (HATU and DIPEA) is controlled at 1:1.2, and the reaction effect is best) and react for 1-2 hours under ice bath conditions. Then add a DMF solution containing gemcitabine (1 mmol). Stir the mixture at room temperature for 24-36 hours. After the reaction is completed, the reaction solution is concentrated under reduced pressure, and column chromatography separation and purification is performed using an eluent of dichloromethane and methanol in a volume ratio of 10 / 1 and 200-300 mesh silica gel as a filling carrier to obtain a nervonic acid-gemcitabine prodrug compound (NA-Gem). The prepared nervonic acid-gemcitabine prodrug compound includes the tail of nervonic acid and the head of a hydrophilic chemotherapy drug.

[0028] Specific preparation method of drug carrier: Accurately weigh 1.0 mg of NA-Gem and fully dissolve it in 2 mL of methanol. Use a nitrogen blower to blow nitrogen to form a uniform film on the container wall. Vacuum dry overnight to remove residual organic solvents. Add 1 mL of ultrapure water and place in a 55°C water bath for 2 h. Adjust the ultrasonic power to an output power of 100 W. After ultrasonic treatment for 5-10 min, obtain a drug carrier.

[0029] If the amount of methanol in the above steps is small and the concentration is high, adding the aqueous phase later will cause most of the drugs to stick to the wall and be difficult to hydrate.

[0030] In the above, the drug can also be solubilized in the micelle by physical encapsulation, that is, by utilizing the hydrophobic interaction between the hydrophobicity of the micelle core and the poorly soluble drugs, which is applicable to most hydrophobic drugs. First, the photosensitizer Ce6 and the prodrug compound are dissolved in an organic solvent miscible with water, such as DMF, DMSO (dimethyl sulfoxide), and then a small amount of water is added to the organic solvent under continuous stirring, and the dialysis bag containing the above mixture is placed in a large amount of water to remove the organic solvent by dialysis.

[0031] The present invention is specifically described below by way of examples.

[0032] Example 1 The specific preparation method of the drug carrier in this embodiment 1 comprises the following steps: (1) Dissolve nervonic acid (1 mmol, 366 mg) in a DMF (5 mL) solution containing HATU (1.2 mmol, 456 mg) and DIPEA (1.2 mmol, 155 mg) (the best effect is achieved when the amount of condensing agent HATU and DIPEA is 1.2-1.5 times that of the reactants in the actual reaction process), and react for 2 h under ice bath conditions. Then add a DMF (5 mL) solution containing gemcitabine (1 mmoL, 263 mg). Stir the mixture at 25°C for 24 h. After the reaction is completed, concentrate the reaction solution under reduced pressure, and perform column chromatography separation and purification using a 10 / 1 volume ratio of dichloromethane and methanol as an eluent and 200-300 mesh silica gel as a filling carrier to obtain a nervonic acid-gemcitabine prodrug compound.

[0033] (2) Weigh 1.0 mg of NA-Gem and fully dissolve it in methanol. Use a nitrogen blower to blow nitrogen to form a uniform film on the container wall. Vacuum dry overnight to remove the residual organic solvent. Add 1 mL of ultrapure water, place in a 55°C water bath for 2 h, and ultrasonicate for 10 min to obtain a drug carrier.

[0034] The critical micelle concentration was determined by fluorescence spectroscopy: Accurately weigh a certain amount of prodrug compound and prepare it into a series of gradient concentrations of test solutions. Take an appropriate amount of pyrene, accurately weigh it, and prepare a 10μg / ml pyrene methanol solution with the organic solvent methanol. Accurately measure 0.1ml of pyrene methanol solution in a sample bottle, evaporate the organic solvent with N2, and then add 10ml of different concentrations of the test solution respectively, sonicate for a short time and shake well, place in a light-proof water bath at 40℃ overnight, and cool to room temperature to obtain a series of concentrations of sample solutions. The specific sample solutions are as follows: Figure 1 shown.

[0035] Reasonably set the instrument parameters, calibrate the instrument, and measure the fluorescence spectra of the test solutions in order from low to high concentrations; find the maximum luminescence intensity near 373nm and 384nm of the fluorescence spectrum of the sample solution, record them as I1 and I3 respectively, calculate I1 / I3, and the change law of I1 / I3 value with the concentration of surfactant solution conforms to the Boltzmann curve, as shown in the following example: Figure 2 As shown, Figure 2 The formula is y=A1−A2 / 1+e (X−X 0 )dx +A; where y is the I1 / I3 value; A1 and A2 are the maximum and minimum values ​​of I1 / I3 respectively; X is the concentration of the surfactant solution; X0 is the midpoint of the curve mutation; dx is the parameter of the curve mutation degree, specifically 1 / 4 of the difference between the horizontal coordinates of the two intersection points of the tangent line at the midpoint of the mutation X0 and y1=A1 and y2=A2; the concentration corresponding to X0 is the critical micelle concentration of the sample.

[0036] It can be seen that this embodiment uses the specific mechanism that pyrene is a strong hydrophobic probe with very low solubility in water. When micelles and other macromolecular systems exist, pyrene preferentially dissolves in the internal hydrophobic regions of these aggregates to measure the critical micelle concentration. The calculated critical micelle concentration is 10.0 mg / L.

[0037] After negative staining with phosphotungstic acid, the morphology of the micelles was observed and photographed using a transmission electron microscope (TEM). The obtained micelle morphology is shown in Figure 3 As shown in the figure, it can be seen that the NA-Gem Nanoparticle drug carrier prepared in this example is basically ellipsoidal or spherical, with a particle size of about 50nm and uniform distribution.

[0038] Evaluation of in vitro cytotoxicity of NA-Gem prodrug compounds using CCK-8 assay: hCMEC / D3 cells and U87-MG cells were cultured at 5×10 3 The cells / well were inoculated in a 96-well plate and cultured in a cell culture incubator at 37°C and 5% CO2 for 24 hours. When the cell density in each well was about 80%, the culture medium was discarded and 100 μL of fresh culture medium diluted with gradient concentrations of prodrug compounds was added. Five parallel wells were set for each concentration and incubated for 48 hours. Then, 10 μL of CCK-8 reagent was added to each well and the incubation continued for one hour. The absorbance value at 450 nm was detected using an ELISA instrument. The cell wells without any sample treatment were used as blank controls to calculate the cell survival rate. The effect of NA-Gem on the cytotoxicity of U87-MG cells is shown in the figure below. Figure 5 As shown in the figure, the cytotoxic effect of NA-Gem on hCMEC / D3 cells is shown in Figure 6 shown.

[0039] This embodiment also constructs a blood-brain barrier model at the cellular level, and uses the prepared drug carrier to encapsulate Ce6, absorbs the drug carrier solution encapsulating Ce6, and places it in the upper layer of the Transwell chamber. The Corning Transwell plate is used to simulate the blood-brain barrier to study the drug penetration ability. Human brain microvascular endothelial cells hCMEC / D3 are added to the upper chamber of the Transwell plate, incubated to a high degree of fusion and to form a good monolayer of cells on the filter membrane, and then candidate drugs are applied, and samples are collected from the basolateral side of the Transwell chamber to detect the amount of drugs that can penetrate the blood-brain barrier at the artificial cell level. Ce6 fluorescence signals are detected in the lower layer of liquid, as shown in the following figure. Figure 4 As shown, it is proved that the prodrug carrier can smoothly carry Ce6 to penetrate the blood-brain barrier.

[0040] Finally, it should be noted that the above embodiments are only used to illustrate the technical solution of the present invention rather than to limit it. Although the present invention has been described in detail with reference to the preferred embodiments, those skilled in the art should understand that the technical solution of the present invention can be modified or replaced by equivalents without departing from the purpose and scope of the technical solution of the present invention, which should be covered by the scope of the claims of the present invention.

Claims

1. A method for preparing a drug carrier, characterized in that: The following steps are involved: (1) fully dissolving the prodrug compound in an organic solvent to obtain a prodrug solution; (2) blowing nitrogen gas onto the prodrug solution using a nitrogen blowing apparatus to form a uniform film on the container wall, and vacuum drying overnight for later use; (3) Residual organic solvent is removed from the film treated in step (2), ultrapure water is added, and the film is placed in a water bath and subjected to ultrasound to obtain a drug carrier.

2. The preparation method according to claim 1, characterized in that In step (1), the prodrug compound is an amphiphilic prodrug compound comprising a neuraminic acid tail and a hydrophilic chemotherapeutic drug head, and the organic solvent comprises methanol.

3. The preparation method according to claim 1, characterized in that: In step (2), the nitrogen blowing film is to place the prodrug solution dissolved in the sample bottle on a nitrogen blowing instrument, adjust the nitrogen flow rate, make the wall-adherent film uniform, and volatilize the organic reagent methanol.

4. The preparation method according to claim 1, characterized in that: In step (3), the water bath treatment is carried out at 40-55°C for 2 hours, and the ultrasonic treatment parameter is 50-100W.

5. The preparation method according to claim 1, characterized in that: The preparation method also includes the step of loading substances including contrast agents and photosensitizers.

6. The drug carrier prepared by the preparation method according to any one of claims 1 to 5, characterized in that: The drug carrier is capable of penetrating the blood-brain barrier.

7. Use of the drug carrier according to claim 6 in the preparation of anti-tumor drugs.

8. The use according to claim 7, characterized in that The tumor is a brain glioma.

Citation Information

Cited By

  • Antineoplastic prodrug and its preparation method and applications

    IE20250449A1

  • Anti-tumor prodrug, and preparation method therefor and use thereof

    WO2026051573A1